TY  - JOUR
AU  - Espinosa-Oliva, Ana M
AU  - García-Miranda, Pablo
AU  - Alonso-Bellido, Isabel María
AU  - Carvajal, Ana E
AU  - González-Rodríguez, Melania
AU  - Carrillo-Jiménez, Alejandro
AU  - Temblador, Arturo J
AU  - Felices-Navarro, Manuel
AU  - García-Domínguez, Irene
AU  - Roca-Ceballos, María Angustias
AU  - Vázquez-Carretero, María D
AU  - García-Revilla, Juan
AU  - Santiago, Marti
AU  - Peral, María J
AU  - Venero, José Luis
AU  - de Pablos, Rocío M
PY  - 2021
DO  - 10.3389/fphar.2021.706439
SN  - 1663-9812
UR  - https://hdl.handle.net/10668/27393
T2  - Frontiers in pharmacology
AB  - Parkinson's disease is a highly prevalent neurological disorder for which there is currently no cure. Therefore, the knowledge of risk factors as well as the development of new putative molecular targets is mandatory. In this sense, peripheral...
LA  - en
KW  - Parkinson’s disease
KW  - galectin-3
KW  - microglia
KW  - neuroinflammation
KW  - peripheral inflammation
TI  - Galectin-3 Deletion Reduces LPS and Acute Colitis-Induced Pro-Inflammatory Microglial Activation in the Ventral Mesencephalon.
TY  - research article
VL  - 12
ER  -